MovDisordV3, PascalFrancis, Corpus, bibRecord, 002B01

Treatment of persistent hemiballism with botulinum toxin type A

Identifieur interne : 002B01 ( PascalFrancis/Corpus ); précédent : 002B00; suivant : 002B02

Treatment of persistent hemiballism with botulinum toxin type A

Auteurs : D. Dressler ; M. Wittstock ; R. Benecke

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:01-0016474

Descripteurs français

Pascal (Inist)
- Hémiballisme, Toxine, Botulisme, Bontoxilysin, Voie intramusculaire, Chimiothérapie, Myorésolutif, Etude cas, Traitement, Indication, Personne âgée, Femelle.

English descriptors

KwdEn :
- Bontoxilysin, Botulism, Case study, Chemotherapy, Elderly, Female, Hemiballismus, Indication, Intramuscular administration, Muscle relaxant, Toxin, Treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Treatment of persistent hemiballism with botulinum toxin type A`
A11	`01`	`1`		`@1 DRESSLER (D.)`
A11	`02`	`1`		`@1 WITTSTOCK (M.)`
A11	`03`	`1`		`@1 BENECKE (R.)`
A14	`01`			`@1 Department of Neurology, Rostock University @2 Rostock @3 DEU @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A20				`@1 1281-1282`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000092814950410`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 8 ref.`
A47	`01`	`1`		`@0 01-0016474`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02C`
C03	`01`	`X`	`FRE`	`@0 Hémiballisme @5 01`
C03	`01`	`X`	`ENG`	`@0 Hemiballismus @5 01`
C03	`01`	`X`	`SPA`	`@0 Hemibalismo @5 01`
C03	`02`	`X`	`FRE`	`@0 Toxine @5 04`
C03	`02`	`X`	`ENG`	`@0 Toxin @5 04`
C03	`02`	`X`	`SPA`	`@0 Toxina @5 04`
C03	`03`	`X`	`FRE`	`@0 Botulisme @5 05`
C03	`03`	`X`	`ENG`	`@0 Botulism @5 05`
C03	`03`	`X`	`SPA`	`@0 Botulismo @5 05`
C03	`04`	`X`	`FRE`	`@0 Bontoxilysin @2 FE @2 FR @5 06`
C03	`04`	`X`	`ENG`	`@0 Bontoxilysin @2 FE @2 FR @5 06`
C03	`04`	`X`	`SPA`	`@0 Bontoxilysin @2 FE @2 FR @5 06`
C03	`05`	`X`	`FRE`	`@0 Voie intramusculaire @5 07`
C03	`05`	`X`	`ENG`	`@0 Intramuscular administration @5 07`
C03	`05`	`X`	`SPA`	`@0 Vía intramuscular @5 07`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 08`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 08`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 08`
C03	`07`	`X`	`FRE`	`@0 Myorésolutif @5 09`
C03	`07`	`X`	`ENG`	`@0 Muscle relaxant @5 09`
C03	`07`	`X`	`SPA`	`@0 Relajante muscular @5 09`
C03	`08`	`X`	`FRE`	`@0 Etude cas @5 17`
C03	`08`	`X`	`ENG`	`@0 Case study @5 17`
C03	`08`	`X`	`SPA`	`@0 Estudio caso @5 17`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`10`	`X`	`FRE`	`@0 Indication @5 19`
C03	`10`	`X`	`ENG`	`@0 Indication @5 19`
C03	`10`	`X`	`SPA`	`@0 Indicación @5 19`
C03	`11`	`X`	`FRE`	`@0 Personne âgée @5 20`
C03	`11`	`X`	`ENG`	`@0 Elderly @5 20`
C03	`11`	`X`	`SPA`	`@0 Anciano @5 20`
C03	`12`	`X`	`FRE`	`@0 Femelle @5 21`
C03	`12`	`X`	`ENG`	`@0 Female @5 21`
C03	`12`	`X`	`SPA`	`@0 Hembra @5 21`
C07	`01`	`X`	`FRE`	`@0 Bactériose`
C07	`01`	`X`	`ENG`	`@0 Bacteriosis`
C07	`01`	`X`	`SPA`	`@0 Bacteriosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Metalloendopeptidases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Metalloendopeptidases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Metalloendopeptidases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`04`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`04`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`05`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Enzyme`
C07	`06`	`X`	`ENG`	`@0 Enzyme`
C07	`06`	`X`	`SPA`	`@0 Enzima`
C07	`07`	`X`	`FRE`	`@0 Homme`
C07	`07`	`X`	`ENG`	`@0 Human`
C07	`07`	`X`	`SPA`	`@0 Hombre`
C07	`08`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`08`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`08`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`09`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`09`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`09`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`10`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`10`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`10`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`11`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`11`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`11`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`12`	`X`	`FRE`	`@0 Trouble neurologique @5 41`
C07	`12`	`X`	`ENG`	`@0 Neurological disorder @5 41`
C07	`12`	`X`	`SPA`	`@0 Trastorno neurológico @5 41`
C07	`13`	`X`	`FRE`	`@0 Mouvement involontaire @5 42`
C07	`13`	`X`	`ENG`	`@0 Involuntary movement @5 42`
C07	`13`	`X`	`SPA`	`@0 Movimiento involuntario @5 42`
N21				`@1 008`

Format Inist (serveur)

NO :	PASCAL 01-0016474 INIST
ET :	Treatment of persistent hemiballism with botulinum toxin type A
AU :	DRESSLER (D.); WITTSTOCK (M.); BENECKE (R.)
AF :	Department of Neurology, Rostock University/Rostock/Allemagne (1 aut., 2 aut., 3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 6; Pp. 1281-1282; Bibl. 8 ref.
LA :	Anglais
CC :	002B02C
FD :	Hémiballisme; Toxine; Botulisme; Bontoxilysin; Voie intramusculaire; Chimiothérapie; Myorésolutif; Etude cas; Traitement; Indication; Personne âgée; Femelle
FG :	Bactériose; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Trouble neurologique; Mouvement involontaire
ED :	Hemiballismus; Toxin; Botulism; Bontoxilysin; Intramuscular administration; Chemotherapy; Muscle relaxant; Case study; Treatment; Indication; Elderly; Female
EG :	Bacteriosis; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Neurological disorder; Involuntary movement
SD :	Hemibalismo; Toxina; Botulismo; Bontoxilysin; Vía intramuscular; Quimioterapia; Relajante muscular; Estudio caso; Tratamiento; Indicación; Anciano; Hembra
LO :	INIST-20953.354000092814950410
ID :	01-0016474

Links to Exploration step

Pascal:01-0016474

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of persistent hemiballism with botulinum toxin type A</title>
<author><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D." last="Dressler">D. Dressler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wittstock, M" sort="Wittstock, M" uniqKey="Wittstock M" first="M." last="Wittstock">M. Wittstock</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benecke, R" sort="Benecke, R" uniqKey="Benecke R" first="R." last="Benecke">R. Benecke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0016474</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0016474 INIST</idno>
<idno type="RBID">Pascal:01-0016474</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of persistent hemiballism with botulinum toxin type A</title>
<author><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D." last="Dressler">D. Dressler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wittstock, M" sort="Wittstock, M" uniqKey="Wittstock M" first="M." last="Wittstock">M. Wittstock</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benecke, R" sort="Benecke, R" uniqKey="Benecke R" first="R." last="Benecke">R. Benecke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Botulism</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Elderly</term>
<term>Female</term>
<term>Hemiballismus</term>
<term>Indication</term>
<term>Intramuscular administration</term>
<term>Muscle relaxant</term>
<term>Toxin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hémiballisme</term>
<term>Toxine</term>
<term>Botulisme</term>
<term>Bontoxilysin</term>
<term>Voie intramusculaire</term>
<term>Chimiothérapie</term>
<term>Myorésolutif</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Indication</term>
<term>Personne âgée</term>
<term>Femelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Treatment of persistent hemiballism with botulinum toxin type A</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DRESSLER (D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WITTSTOCK (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BENECKE (R.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1281-1282</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000092814950410</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>8 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0016474</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hémiballisme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Hemiballismus</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hemibalismo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Toxine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Toxin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Toxina</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Botulisme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Botulism</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Botulismo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Voie intramusculaire</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Intramuscular administration</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vía intramuscular</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Myorésolutif</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Muscle relaxant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Relajante muscular</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Case study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Indication</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Indication</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Indicación</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Elderly</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Anciano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Femelle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Female</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Hembra</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Bactériose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>41</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>42</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>42</s5>
</fC07>
<fN21><s1>008</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 01-0016474 INIST</NO>
<ET>Treatment of persistent hemiballism with botulinum toxin type A</ET>
<AU>DRESSLER (D.); WITTSTOCK (M.); BENECKE (R.)</AU>
<AF>Department of Neurology, Rostock University/Rostock/Allemagne (1 aut., 2 aut., 3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 6; Pp. 1281-1282; Bibl. 8 ref.</SO>
<LA>Anglais</LA>
<CC>002B02C</CC>
<FD>Hémiballisme; Toxine; Botulisme; Bontoxilysin; Voie intramusculaire; Chimiothérapie; Myorésolutif; Etude cas; Traitement; Indication; Personne âgée; Femelle</FD>
<FG>Bactériose; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Trouble neurologique; Mouvement involontaire</FG>
<ED>Hemiballismus; Toxin; Botulism; Bontoxilysin; Intramuscular administration; Chemotherapy; Muscle relaxant; Case study; Treatment; Indication; Elderly; Female</ED>
<EG>Bacteriosis; Infection; Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Neurological disorder; Involuntary movement</EG>
<SD>Hemibalismo; Toxina; Botulismo; Bontoxilysin; Vía intramuscular; Quimioterapia; Relajante muscular; Estudio caso; Tratamiento; Indicación; Anciano; Hembra</SD>
<LO>INIST-20953.354000092814950410</LO>
<ID>01-0016474</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B01 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002B01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:01-0016474
   |texte=   Treatment of persistent hemiballism with botulinum toxin type A
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Treatment of persistent hemiballism with botulinum toxin type A

Treatment of persistent hemiballism with botulinum toxin type A

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri